HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
BIOBOARD - INDIA
Biocon receives marketing authorization for novel biologic itolizumab for psoriasis
Biocon, Asia's premier biotechnology company received marketing authorization from the Drugs Controller General of India (DCGI) for its novel biologic itolizumab, anti-CD6 molecule, for the treatment of chronic plaque psoriasis.

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second novel biologic developed by Biocon at Asia's largest biotech hub in Bangalore.

This approval paves the way for the launch of Biocon's Alzumab TM in India, later during 2013. Alzumab TM is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab TM will be marketed by Biocon's Immunotherapy Division. Alzumab TM, will be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.

Commenting on this development Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, "We are very excited to receive this marketing authorization for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo. We also intend to file a US IND shortly to enable us to embark on a global clinical development plan. This is a defining moment for Biocon as it reaches a significant milestone in its mission of delivering affordable innovation to patients worldwide."

Alzumab (TM) is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting 2-3 % of Indian population. The global psoriasis market size is estimated to cross $8 billion by 2016.

Itolizumab has shown promising preclinical and clinical efficacy in other auto immune diseases like rheumatoid arthritis and multiple sclerosis. The company aims to file a US IND in 2013 to facilitate global clinical trials in psoriasis, rheumatoid arthritis and other indications as a subcutaneous formulation. Biocon plans to develop this molecule with a global partner for various markets across the world.

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017 heralds a new future of innovation
news Sanner receives Zero Defect Award
news AdAlta pioneers novel drug for rare lung disease
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy